Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals.


Journal

Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742

Informations de publication

Date de publication:
01 2021
Historique:
received: 21 09 2019
accepted: 24 03 2020
revised: 19 02 2020
pubmed: 30 4 2020
medline: 13 10 2021
entrez: 30 4 2020
Statut: ppublish

Résumé

Gut CD4

Identifiants

pubmed: 32346082
doi: 10.1038/s41385-020-0286-6
pii: S1933-0219(22)00122-2
doi:

Substances chimiques

Biomarkers 0
CCL20 protein, human 0
CCL28 protein, human 0
Chemokine CCL20 0
Chemokines, CC 0
Cytokines 0
Inflammation Mediators 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-228

Références

Brenchley, J. M. et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749–759 (2004).
pubmed: 15365096 pmcid: 2211962 doi: 10.1084/jem.20040874
Mehandru, S. et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200, 761–770 (2004).
pubmed: 15365095 pmcid: 2211967 doi: 10.1084/jem.20041196
Guadalupe, M. et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77, 11708–11717 (2003).
pubmed: 14557656 pmcid: 229357 doi: 10.1128/JVI.77.21.11708-11717.2003
Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).
pubmed: 17115046 doi: 10.1038/nm1511
Mudd, J. C. & Brenchley, J. M. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression. J. Infect. Dis. 214(Suppl 2), S58–S66 (2016).
pubmed: 27625432 pmcid: 5021240 doi: 10.1093/infdis/jiw258
Annunziato, F. et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849–1861 (2007).
pubmed: 17635957 pmcid: 2118657 doi: 10.1084/jem.20070663
Brenchley, J. M. et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112, 2826–2835 (2008).
pubmed: 18664624 pmcid: 2556618 doi: 10.1182/blood-2008-05-159301
El Hed, A. et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J. Infect. Dis. 201, 843–854 (2010).
pubmed: 20144043 doi: 10.1086/651021 pmcid: 20144043
Gosselin, A. et al. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J. Immunol. 184, 1604–1616 (2010).
pubmed: 20042588 doi: 10.4049/jimmunol.0903058 pmcid: 20042588
Gosselin, A. et al. HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. AIDS 31, 35–48 (2017).
pubmed: 27835617 doi: 10.1097/QAD.0000000000001309
Wacleche, V. S. et al. New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology 13, 59 (2016).
pubmed: 27553844 pmcid: 4995622 doi: 10.1186/s12977-016-0293-6
Raffatellu, M. et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat. Med. 14, 421–428 (2008).
pubmed: 18376406 pmcid: 2901863 doi: 10.1038/nm1743
Chege, D. et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25, 741–749 (2011).
pubmed: 21378536 doi: 10.1097/QAD.0b013e328344cefb
Kim, C. J. et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J. Immunol. 191, 2164–2173 (2013).
pubmed: 23894197 doi: 10.4049/jimmunol.1300829
Eyerich, S. et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Investig. 119, 3573–3585 (2009).
pubmed: 19920355
Fernandes, S. M. et al. Enteric mucosa integrity in the presence of a preserved innate interleukin 22 compartment in HIV type 1-treated individuals. J. Infect. Dis. 210, 630–640 (2014).
pubmed: 24604817 doi: 10.1093/infdis/jiu126
Kim, C. J. et al. A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol. 5, 670–680 (2012).
pubmed: 22854709 doi: 10.1038/mi.2012.72
Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009).
pubmed: 19836068 pmcid: 19836068 doi: 10.1016/j.cell.2009.09.033
Sano, T. et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell 163, 381–393 (2015).
pubmed: 26411290 pmcid: 4621768 doi: 10.1016/j.cell.2015.08.061
Lee, J. Y. et al. Serum amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell 180, 79–91.e16 (2020).
pubmed: 31866067 doi: 10.1016/j.cell.2019.11.026 pmcid: 31866067
Acosta-Rodriguez, E. V. et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8, 639–646 (2007).
pubmed: 17486092 doi: 10.1038/ni1467 pmcid: 17486092
Cosmi, L. et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med 205, 1903–1916 (2008).
pubmed: 18663128 pmcid: 2525581 doi: 10.1084/jem.20080397
Trifari, S., Kaplan, C. D., Tran, E. H., Crellin, N. K. & Spits, H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10, 864–871 (2009).
pubmed: 19578368 doi: 10.1038/ni.1770 pmcid: 19578368
Page, E. E. et al. Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infection. J. Acquir Immune Defic. Syndr. 67, 227–235 (2014).
pubmed: 25314246 doi: 10.1097/QAI.0000000000000294 pmcid: 25314246
Ryan, E. S. et al. Loss of function of intestinal IL-17 and IL-22 producing cells contributes to inflammation and viral persistence in SIV-infected rhesus macaques. PLoS Pathog. 12, e1005412 (2016).
pubmed: 26829644 pmcid: 4735119 doi: 10.1371/journal.ppat.1005412
Kok, A. et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunol. 8, 127–140 (2015).
pubmed: 24985081 doi: 10.1038/mi.2014.50 pmcid: 24985081
Schuetz, A. et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 10, e1004543 (2014).
pubmed: 25503054 pmcid: 4263756 doi: 10.1371/journal.ppat.1004543
Loiseau, C. et al. CCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals. Mucosal Immunol. 9, 1137–1150 (2016).
pubmed: 26883727 doi: 10.1038/mi.2016.7 pmcid: 26883727
Micci, L. et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J. Clin. Investig. 125, 4497–4513 (2015).
pubmed: 26551680 doi: 10.1172/JCI81400 pmcid: 26551680
Loiseau C. et al. Increase of CXCR3+ T cells impairs Th17 cells recruitment in the small intestine mucosa through IFN-gamma and IL-18 during treated HIV-1 infection. J. Infect. Dis. 220, 830–840 (2019).
pubmed: 30880342 doi: 10.1093/infdis/jiz123
Pan, J. et al. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J. Immunol. 165, 2943–2949 (2000).
pubmed: 10975800 doi: 10.4049/jimmunol.165.6.2943
Munoz, M. et al. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity 42, 321–331 (2015).
pubmed: 25680273 doi: 10.1016/j.immuni.2015.01.011
Sandler, N. G. et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203, 780–790 (2011).
pubmed: 21252259 pmcid: 3071127 doi: 10.1093/infdis/jiq118
Knudsen, T. B. et al. Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1-infected individuals. J. Infect. Dis. 214, 1198–1204 (2016).
pubmed: 27354366 doi: 10.1093/infdis/jiw263
Serrano-Villar, S. et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 10, e1004078 (2014).
pubmed: 24831517 pmcid: 4022662 doi: 10.1371/journal.ppat.1004078
Kunkel, E. J. et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J. Clin. Investig. 111, 1001–1010 (2003).
pubmed: 12671049 doi: 10.1172/JCI17244
Mellado, M. et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20, 2497–2507 (2001).
pubmed: 11350939 pmcid: 125458 doi: 10.1093/emboj/20.10.2497
Sohy, D., Parmentier, M. & Springael, J. Y. Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J. Biol. Chem. 282, 30062–30069 (2007).
pubmed: 17715128 doi: 10.1074/jbc.M705302200
Isik, N., Hereld, D. & Jin, T. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS ONE 3, e3424 (2008).
pubmed: 18923649 pmcid: 2566588 doi: 10.1371/journal.pone.0003424
Mavigner, M. et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J. Clin. Investig. 122, 62–69 (2012).
pubmed: 22156200 doi: 10.1172/JCI59011 pmcid: 22156200
Kueck, T., Cassella, E., Holler, J., Kim, B. & Bieniasz, P. D. The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. eLife 7, e38867 (2018).
pubmed: 30132758 pmcid: 6120754 doi: 10.7554/eLife.38867
McKinnon, L. R. et al. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J. Immunol. 187, 6032–6042 (2011).
pubmed: 22048765 doi: 10.4049/jimmunol.1101836 pmcid: 22048765
Joag, V. R. et al. Identification of preferential CD4+ T-cell targets for HIV infection in the cervix. Mucosal Immunol. 9, 1–12 (2016).
pubmed: 25872482 doi: 10.1038/mi.2015.28 pmcid: 25872482
Mowat, A. M. & Agace, W. W. Regional specialization within the intestinal immune system. Nat. Rev. Immunol. 14, 667–685 (2014).
pubmed: 25234148 doi: 10.1038/nri3738 pmcid: 25234148

Auteurs

Manon Nayrac (M)

INSERM, UMR1043, Toulouse, F-31300, France.

Mary Requena (M)

CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300, France.

Claire Loiseau (C)

INSERM, UMR1043, Toulouse, F-31300, France.
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.

Michelle Cazabat (M)

CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300, France.

Bertrand Suc (B)

Université Toulouse III Paul Sabatier, Toulouse, F-31300, France.
CHU de Toulouse, Service de Chirurgie Générale et Digestive, Toulouse, F-31300, France.

Nicolas Carrere (N)

Université Toulouse III Paul Sabatier, Toulouse, F-31300, France.
CHU de Toulouse, Service de Chirurgie Générale et Digestive, Toulouse, F-31300, France.

Karl Barange (K)

CHU de Toulouse, Service d'Hépato-Gastro-Entérologie, Toulouse, F-31300, France.

Laurent Alric (L)

Université Toulouse III Paul Sabatier, Toulouse, F-31300, France.
CHU de Toulouse, Service de Médecine Interne, Toulouse, F-31300, France.
IRD UMR152, Toulouse, F-31400, France.

Guillaume Martin-Blondel (G)

INSERM, UMR1043, Toulouse, F-31300, France.
Université Toulouse III Paul Sabatier, Toulouse, F-31300, France.
CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, F-31300, France.

Jacques Izopet (J)

INSERM, UMR1043, Toulouse, F-31300, France.
CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300, France.
Université Toulouse III Paul Sabatier, Toulouse, F-31300, France.

Pierre Delobel (P)

INSERM, UMR1043, Toulouse, F-31300, France. delobel.p@chu-toulouse.fr.
Université Toulouse III Paul Sabatier, Toulouse, F-31300, France. delobel.p@chu-toulouse.fr.
CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, F-31300, France. delobel.p@chu-toulouse.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH